{
    "relation": [
        [
            "",
            "H1N1 Vaccine 15 Mcg",
            "H1N1 Vaccine 30 Mcg"
        ],
        [
            "Description",
            "Participants received 15 mcg of H1N1 vaccine by intramuscular injection on Days 0 and 21.",
            "Participants received 30 mcg of H1N1 vaccine by intramuscular injection on Days 0 and 21."
        ]
    ],
    "pageTitle": "CSL H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00943488?sect=Xl0156&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042992201.62/warc/CC-MAIN-20150728002312-00233-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 858141063,
    "recordOffset": 858125125,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details Participants were healthy adult males and females recruited from existing volunteer populations and from the communities at large around the clinical sites. Participants were enrolled between 07AUG2009 and 21AUG2009 Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Biological: Inactivated H1N1 Vaccine Intervention: Influenza Condition: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety/Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Double\u00a0Blind\u00a0(Subject,\u00a0Investigator,\u00a0Outcomes\u00a0Assessor); \u00a0 Primary\u00a0Purpose:\u00a0Prevention Study Design: Interventional Study Type:",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 H1N1 Vaccine 15 Mcg \u00a0 \u00a0 H1N1 Vaccine 30 Mcg \u00a0 STARTED \u00a0 \u00a0 204 \u00a0 \u00a0 204 \u00a0 COMPLETED \u00a0 \u00a0 203 \u00a0 \u00a0 202 \u00a0 NOT COMPLETED \u00a0 \u00a0 1 \u00a0 \u00a0 2 \u00a0 \u00a0 Baseline Characteristics \u00a0 Hide Baseline Characteristics Population Description Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. No text entered.",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}